Live market news
Stocks
MNOV

MediciNova Inc.

MNOVStockUnited States

1.45USD0.00 (0.00%)Live · 5 Nov, 20:59 UTC

See in Charts

Key figures

Previous close: 1.45
Open: 1.45
Day range: 1.45 – 1.47
52-week range: —
Volume: 139K

Latest news on MNOVranked by Oyticker for market impact

65Impact
NeutralMajor information24 Sept 2026 · 10:00 UTC · Global · Short term
MediciNova completes double-blind enrollment in Phase 2b/3 ALS trial; topline results expected end-2026
MediciNova announced completion of last patient, last visit in the double-blind portion of COMBAT-ALS, a 234-patient Phase 2b/3 trial of MN-166 (ibudilast) for ALS treatment. Topline results are expected by end-2026, with full study completion in March 2027.
MNOVBiopharmaceuticalsNeurology

In detailthe same figures as in Oyticker Charts

Performance

1D0.0%

Ranges & volume

Day1.45 – 1.47

52 weeks—

Open: 1.45
Prev. close: 1.45

Volume 139Kavg —

Risk · 1 year

Not enough historyRisk needs at least a month of daily sessions.

Seasonality

Not enough historySeasonality needs several months of data.

SEC filings

What MNOV filed

All its filings

28 Sept 2026
Material agreement (opens the document on sec.gov)8-K
2 Sept 2026
Agreement ended (opens the document on sec.gov)8-K
19 Aug 2026
Executive or director change (opens the document on sec.gov)8-K
13 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
24 Jun 2026
Shareholder vote results (opens the document on sec.gov)8-K
14 May 2026
Quarterly report (opens the document on sec.gov)10-Q

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Key figures

Latest news on MNOVranked by Oyticker for market impact

MediciNova completes double-blind enrollment in Phase 2b/3 ALS trial; topline results expected end-2026

In detailthe same figures as in Oyticker Charts

What MNOV filed